Identifying the Candidates Who Will Benefit From Extended Pelvic Lymph Node Dissection at Radical Prostatectomy Among Patients With Prostate Cancer

Guanjie Yang; Jun Xie; Yadong Guo; Jing Yuan; Ruiliang Wang; Changcheng Guo; Bo Peng; Xudong Yao; Bin Yang

doi:10.3389/fonc.2021.790183

Identifying the Candidates Who Will Benefit From Extended Pelvic Lymph Node Dissection at Radical Prostatectomy Among Patients With Prostate Cancer

Front Oncol. 2022 Jan 26:11:790183. doi: 10.3389/fonc.2021.790183. eCollection 2021.

Authors

Guanjie Yang¹, Jun Xie², Yadong Guo¹, Jing Yuan¹, Ruiliang Wang¹, Changcheng Guo¹, Bo Peng^{1

2}, Xudong Yao^{1

2}, Bin Yang¹

Affiliations

¹ Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
² Shanghai Clinical College, Anhui Medical University, Shanghai, China.

Abstract

Purpose: The therapeutic effect of extended pelvic lymph node dissection (PLND) in prostate cancer (PCa) patients is still controversial. The aim of this study was to identify the PCa patients who may benefit from extended PLND based on the 2012 Briganti nomogram.

Materials and methods: PCa patients who underwent radical prostatectomy (RP) plus PLND between 2010 and 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The probability of lymph node invasion (LNI), determined using the 2012 Briganti nomogram, was used to stratify the patients. The endpoints were overall survival (OS) and cancer-specific survival (CSS). Propensity score matching (PSM) was performed to account for potential differences between patients with and without extended PLND. Univariable and multivariable Cox regression was used to analyze the association between the number of removed nodes (NRN) and survival. Kaplan-Meier analysis was performed to estimate OS and CSS. Extended PLND was defined as NRN >75th percentile.

Results: A total of 27,690 patients were included in the study. NRN was not an independent predictor of OS (p = 0.564). However, in patients with probability of LNI ≥37, multivariable analyses showed that increased NRN was associated with improved OS (hazard ratio [HR] = 0.963; p = 0.002). The 5-y OS rate was significantly higher for patients with NRN ≥12 than those with NRN <12 (94.9% vs. 91.9%, respectively; p = 0.015). In the PSM cohort, among patients with probability of LNI ≥37, multivariable analyses showed that increased NRN was associated with improved OS (HR = 0.961; p = 0.004). In addition, the 5-y OS rate was significantly higher for patients with NRN ≥12 than those with NRN <12 (94.9% vs. 89.8%, respectively; p = 0.002). However, NRN was not an independent predictor of CSS in any LNI risk subgroup (all p >0.05).

Conclusion: Extensive PLND might be associated with improved survival in PCa patients with a high risk of LNI, which supports the use of extended PLND in highly selected PCa patients. The results need to be validated in prospective studies with long-term follow-up.

Keywords: lymph node dissection; nomogram; prostate cancer; prostatectomy; survival.